Combined Therapeutics wins $250,000 MilliporeSigma Advance Biotech Grant

MilliporeSigma has awarded MIT spin-out Combined Therapeutics a cheque for $250,000 as the winner of its 2020 Advance Biotech Grant.

Combined Therapeutics (CTx) is an early stage startup developing next generation virotherapies targeted with nucleic acids. The pre-clinical biotech aims to develop therapies to treat liver cancer using its targeted oncolytic platform.

The firm – founded by MIT professors Robert Langer and Dan Anderson, along with entrepreneur Romain Micol – was the prestigious winner Thursday of the MilliporeSigma Advance Biotech Grant, part of the Xconomy 2020 Awards Event.

The Advance Biotech Grant, sponsored and presented by MilliporeSigma, the life science business of Merck KGaA, looks to help resolve the limitations for emerging biotech companies in accessing the equipment, products, and services they need to discover, develop and push the next generation of drugs to market. The rotating grant program began in 2014 and runs every six months in Europe, North America, and Asia with over €4 million ($4.7 million) having already been awarded.

Senior scientist Lauren Speciner picked up the award for Combined Therapeutics during the virtual event, and thanked MilliporeSigma in her acceptance speech.

“We’ve already had some really great discussions [with them]. They provided good input and helped us to give some solutions to some of the process issues that we’ve been having,” she told delegates. “This grant will help us to scale up quickly and create [nucleic acid based combined immunotherapeutics] and we look forward to continue working with them.”

Combined Therapeutics will be able to use the $250,000 USD for the purchase of:

Andrew Bulpin, head of Process Solutions at MilliporeSigma, introduced the award, explaining how MilliporeSigma strives to help biotech startups understand the challenges in the quest to push the next generation of drugs to market.

“Whether you operate in the field of monoclonal antibodies, and recombinant antibody, drug conjugates, vaccines, or gene therapies, our products, services and experts are there to help you find the best way to move your molecule to the next scale faster. Through our advanced biotech grant program, we recognize stand out emerging biotech companies and help them navigate their path to commercialization.”

Combined Therapeutics was one three finalists from over 50 applicants. The other two finalists – Frank Jing, Tenaya Therapeutics and Tim Pelura, Respana Therapeutics – both received $10,000 in products and services for their respective companies.